Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

Автор: Фомин Дмитрий Кириллович, Борисова Ольга Анатольевна, Назаров Андрей Александрович, Пятницкий И.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 2 т.14, 2014 года.

Бесплатный доступ

Представлен обзор литературных данных о современных подходах к тактике лечения пациентов с нейробластомой. Показана эффективность применения различных схем радионуклидной терапии с использованием 131І-МИБГ в режиме мототерапии или при сочетании с химиотерапией. Описаны основные побочные эффекты при проведении 131І-МИБГ терапии и возможные способы их лечения.

Нейробластома, 131і-мибг, радиойодтерапия, детская онкология, химиотерапия

Короткий адрес: https://sciup.org/14955442

IDR: 14955442

Список литературы Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

  • Attiyeh E., London W., Mosse Y. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma.//N Engl J Med. 2005; V. 353. P. 2243-2253.
  • Armour A., Mairs R., Gaze M. et al. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.//Br J Cancer. 1994. V. 70. P. 445-448.
  • Armour A., Cunningham S., Gaze M. et al. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.//Br J Cancer. 1997. V. 75. P. 470-476.
  • Brans B., Laureys G., Schelfhout V., et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo.//European Journal of Nuclear Medicine. 1998. V. 25. P. 144-149.
  • Bown N., Cotterill S., Lastowska M. et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.//N Engl J Med. 1999. V. 340. P. 1954-1961.
  • Brodeur G., Pritchard J., Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.//Journal of Clinical Oncology. 1993. V.11 P. 1466-1477.
  • Buck J., Bruchelt G., Girgert R. et al. Specific uptake of m-iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.,//Cancer Res. 1985. V. 45. P. 6366-6370.
  • Castellani M., Chiti A., Seregni E. et al. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.//Q J Nucl Med. 2000. V. 44. P.77-87.
  • Carlin S., Mairs R., McCluskey A. et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-iodobenzylguanidine by neuroblastoma tumors.//Clin Cancer Res. 2003. V. 9. P. 3338-3344.
  • Claudiani F., Garaventa A., Bertolazzi L. et al. metaiodobenzylguanidine therapy in advanced neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 224-227.
  • De Kraker J., Hoefnagel C., Caron H., et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma.//Eur J Cancer. 1995. V. 31A. P. 600-602.
  • De Kraker J., Hoefnagel K., Verschuur A. et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.//Eur J Cancer. 2008. V.44. P. 551-556.
  • Dubois S., Messina J., Maris J. et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.//Journal of Clinical Oncology. 2004. V.22. P. 2452-2460.
  • DuBois S., Kalika Y., Lukens J. et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.//J Pediatr Hematol Oncol. 1999. V. 21. P. 181-189.
  • Ehninger G., Klingebiel T., Kumbier I. et al. Stability and pharmacokinetics of m-iodobenzylguanidine in patients.//Cancer Res. 1987. V. 47. P. 6147-6149.
  • Garaventa A., Bellagamba O., Lo Piccolo M. et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.//Br J Cancer. 1999. V. 81. P. 1378-1384.
  • Garaventa A., Guerra P., Arrighini A. et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine.//Cancer. 1991. V. 67. P. 922-928.
  • Gaze M., Chang Y., Flux G. Feasibility of dosimetry-based high-dose 13 П-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.//Cancer Biother Radiopharm. 2005. V. 20. P. 195-199.
  • Goodman M., Gurney J., Smith M. et al. Sympathetic Nervous System Tumors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program. 1999. P. 65-72.
  • Hoefnagel C., Voute P., De Kraker J. et al. metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 202-206.
  • Hor G., Maul F., Kornhuber B. et al. Outcome of metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med. 1991. V. 35. P. 207-215.
  • Howard J., Maris J., Kersun L. et al. Tumor response and toxicity with multiple infusions of high dose (131)I-MIBG for refractory neuroblastoma.//Pediatr Blood Cancer. 2005. V. 44. P. 232-239.
  • Howman-Giles R., Shaw P., Uren R. et al. Neuroblastoma and other neuroendocrine tumors.//Semin Nucl Med. 2007. V. 37. P. 286-302.
  • Hutchinson R., Sisson J., Miser J. et al. Long-term results of metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 237-240.
  • Hutchinson R., Sisson J., Shapiro B. et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma.//Am J Clin Oncol. 1992. V. 15. P. 226-232.
  • Iavarone A., Lasorella A., Servidei T. et al. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells.//J Nucl Biol Med. 1991. V. 35. P. 186-190.
  • Iavarone A., Lasorella A., Servidei T. et al. Uptake and storage of miodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines.//Cancer Res. 1993. V. 53. P. 304-309.
  • Kang T., Brophy P., Hickeson M. et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.//J Pediatr Hematol Oncol. 2003 V. 25. P. 769-773.
  • Klingebiel T., Treuner J., Ehninger G., et al. -metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.//Cancer Chemother Pharmacol. 1989. V. 25. P. 143-148.
  • Klingebiel T., Feine U., Treuner J. et al. Treatment of neuroblastoma with metaiodobenzylguanidine: long-term results in 25 patients.//J Nucl Biol Med. 1991. V. 35. P. 216-219.
  • Lashford L., Lewis I., Fielding S. et al. Phase I/F; II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.//Journal of Clinical Oncology. 1992. V. 10. P. 1889-1896.
  • Lashford L., Moyes J., Ott R. et al. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.//European Journal of Nuclear Medicine. 1988. V. 13. P. 574-577.
  • Lode H., Bruchelt G., Seitz G. et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression.//Eur J Cancer. 1995. V. 31A. P. 586-590.
  • Matthay K., Panina C., Huberty J. et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.//J Nucl Med. 2001. V. 42. P. 1713-1721.
  • Look A., Hayes F., Shuster J. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.//Journal of Clinical Oncology. 1991. V. 9. P. 581-591.
  • Lumbroso J., Hartmann O., Schlumberger M. Therapeutic use of metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators.//J Nucl Biol Med. 1991. V. 35. P. 220-223.
  • Mairs R., Livingstone A., Gaze M. et al. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.//Br J Cancer. 1994. V. 70. P. 97-101.
  • Mastrangelo R., Tornesello A., Lasorella A. et al. Optimal use of the 131-Imetaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma.//J Neurooncol. 1997. V. 31. P. 153-158.
  • Mastrangelo R., Tornesello A., Riccardi R. et al. A new approach in the treatment of stage IV neuroblastoma using a combination of meta-iodobenzylguanidine (MIBG) and cisplatin.//Eur J Cancer. 1995. V. 31A. P. 606-611.
  • Mastrangelo R., Tornesello A. Children's Oncology Group.//Journal of Clinical Oncology. 2005. V. 23. P. 6459-6465.
  • Mastrangelo S., Tornesello A., Diociaiuti L. et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.//Br J Cancer. 2001. V. 84. P. 460-464.
  • Matthay K., DeSantes K., Hasegawa B. et al. Phase I dose escalation of 131Imetaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.//Journal of Clinical Oncology. 1998. V. 16. P. 229-236.
  • Matthay K., Quach A., Huberty J. et al. 131I-Metaiodobenzylguanidine (131I-MIBG) Double Infusion with Autologous Stem Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Phase I study.//Journal of Clinical Oncology. 2008. V. 23. P. 200-215.
  • Matthay K., Huberty J., Hattner R. et al. Efficacy and safety of metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 244-247.
  • Matthay K., Perez C., Seeger R. et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.//Journal of Clinical Oncology. 1998. V. 16. P. 1256-1264.
  • Matthay K., Villablanca J., Seeger R. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999. V. 341. P. 1165-1173.
  • Matthay K., Reynolds C., Seeger R. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study.//Journal of Clinical Oncology. 2008. V. 54. P. 432-439.
  • McCluskey A., Boyd M., Ross S. et al. meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.//Clin Cancer Res. 2005. V. 11. P. 7929-7937.
  • Meco D., Lasorella A., Riccardi A. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines Eur J Cancer. 1999. V. 35. P. 1227-1234.
  • Modak S., Pandit-Taskar N., Kushner B. et al. Transient sialoadenitis: A complication of (131)I-metaiodobenzylguanidine therapy.//Pediatr Blood Cancer. 2007. V. 45. P. 567-572.
  • Montaldo P., Lanciotti M., Casalaro A. et al. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms.//Cancer Res. 1991. V. 51. P. 4342-4346.
  • Montaldo P., Carbone R., Ponzoni M. et al. gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells.//Cancer Res. 1992. V. 52. P. 4960-4964.
  • Montaldo P., Raffaghello L., Guarnaccia F. et al. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells.//Int J Cancer. 1996. V. 67. P95-100.
  • Schmidt M., Lal A., Seeger R. et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.//Journal of Clinical Oncology. 2005. V. 23. P. 6474-6480.
  • Seeger R., Brodeur G., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.//N Engl J Med. 1985. V. 313. P. 1111-1116.
  • Sisson J., Shapiro B., Hutchinson R. et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.//European Journal of Nuclear Medicine. 1994. V. 21. P. 46-52.
  • Shimada H., Chatten J., Newton W., Jr et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.//J Natl Cancer Inst. 1984. V. 73. P. 405-416.
  • Smets L., Loesberg C., Janssen M. et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.//Cancer Res. 1989. V. 49. P. 2941-2944.
  • Treuner J., Feine U., Niethammer D. et al. Scintigraphic imaging of neuroblastoma with iodobenzylguanidine.//Lancet. 1984. V. 1. P. 333-334.
  • Troncone L., Rufini V., Riccardi R. The use of metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy.//J Nucl Biol Med. 1991. V. 35. P. 232-236.
  • Voute P., van der Kleij A., De Kraker J. et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV.//Eur J Cancer. 1995. V. 31A. P. 596-600.
  • Wafelman A., Nortier Y., Rosing H., et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.//Nucl Med Commun. 1995. V. 16. P. 767-772.
  • Shimada H., Chatten J., Newton W. et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.//J Natl Cancer Inst. 1984. V. 73. P. 405-416.
  • Cunningham S., Boyd M., Brown M. et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma.//Med Pediatr Oncol. 2000. V. 35. P. 708-711.
  • Matthay K., Panina C., Huberty J. et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.//J Nucl Med. 2001. V. 42. P. 1713-1721.
  • Matthay K., Yanik G., Messina J. et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.//Journal of Clinical Oncology. 2007. V. 25. P. 1054-1060.
  • Brans B., Monsieurs M., Laureys G. et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.//Med Pediatr Oncol. 2002. V. 38. P. 41-46.
  • Dubois S., Messina J., Maris J. et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.//Journal of Clinical Oncology. 2004. V. 22. P. 2452-2460.
  • Van Santen H., de Kraker J., van Eck B. et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.//Cancer. 2002. V. 94. P. 2081-2089.
  • Van Santen H., de Kraker J., Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma.//Eur J Cancer. 2005. V. 41. P. 1767-1774.
Еще
Статья научная
SciUp 2024 © 2024 ©